"BioTrove has been proactive in partnering with scientists and clinicians to enable higher-throughput research leading to advances in healthcare," added Bird. "The company is a blueprint for sound business strategy and demonstrates that quality and a collaborative spirit remain essential characteristics for successful life sciences companies."
In the past year, BioTrove partnered with OSI Pharmaceuticals, the BloodCenter of Wisconsin, and Constellation Pharmaceuticals to assist research efforts with the company's innovative technologies. These research endeavors ranged from lead compound discovery to single nucleotide polymorphism (SNP) genotyping on the OpenArray(R) system to investigating novel therapeutic targets with the RF-MS system. Researchers often appreciate a company that takes interest in research endeavors and provides value-added support to its customers. Ultimately, BioTrove has demonstrated its commitment to enabling research efforts to advance healthcare through strategic customer partnerships.
For exhibiting best practices in growth strategy, BioTrove is an ideal recipient of the Frost & Sullivan 2009 North American Drug Discovery Technologies Growth Strategy Leadership of the Year Award. Each year, Frost & Sullivan presents this award to the company that has demonstrated an exceptional growth strategy within the industry.
Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance thro
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved